LncRNA H19: A Novel Biomarker in Cardiovascular Disease

被引：1

作者：

Li, Xiaojun ^{[1
]}

Zhang, Yugui ^{[2
]}

Ding, Zhaoran ^{[3
]}

Chen, Yijun ^{[4
]}

Wang, Wei ^{[5
]}

机构：

[1] Guangzhou Univ Chinese Med, Basic Med Coll, Guangzhou, Peoples R China

[2] Guangzhou Univ Chinese Med, Coll Pharm, Guangzhou, Peoples R China

[3] Gansu Univ Chinese Med, Coll Integrat Med, Lanzhou, Peoples R China

[4] Guangzhou Univ Chinese Med, Sch Basic Med, Guangzhou, Peoples R China

[5] Guangzhou Univ Tradit Chinese Med, Univ Town, Sch Basic Med, 232 Waihuan East Rd, Guangzhou, Guangdong, Peoples R China

来源：

ACTA CARDIOLOGICA SINICA | 2024年 / 40卷 / 02期

基金：

中国国家自然科学基金;

关键词：

Cardiovascular disease; LncRNA H19; Novel biomarker; LONG NONCODING RNA; REGULATES CARDIOMYOCYTE APOPTOSIS; ISCHEMIA-REPERFUSION INJURY; EXPRESSION; AXIS; MECHANISM; MARKER; GROWTH; CELLS;

D O I：

10.6515/ACS.202403_40(2).20230925A

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Cardiovascular disease is a major cause of death and disability worldwide. Recently, increasing evidence has demonstrated that long non -coding RNAs (lncRNAs) play critical roles in the pathogenesis of cardiovascular diseases, including atherosclerosis, coronary artery disease, dilated cardiomyopathy, diabetic cardiomyopathy, aortic dissection, and more. LncRNA H19 was the first to be described as a non -protein -coding mRNA-like molecule. A large number of studies have found that lncRNA H19 is related to the pathophysiological processes of cardiovascular diseases, and it is emerging as a potential key regulator of various heart diseases. In this review, we aim to summarize the role of lncRNA H19 in cardiovascular diseases in order to provide a theoretical basis for its potential use as a new therapeutic target in the future.

引用

页码：172 / 181

页数：10

共 50 条

[1] Circulating lncRNA H19 in plasma as a novel biomarker for breast cancer
Zhang, Kaijiong
Luo, Zhenglian
Zhang, Yi
Zhang, Li
Wu, Lichun
Liu, Lian
Yang, Jie
Song, Xiaoyu
Liu, Jinbo
CANCER BIOMARKERS, 2016, 17 (02) : 187 - 194
[2] The multifaceted actions of the lncRNA H19 in cardiovascular biology and diseases
Busscher, Denise
Boon, Reinier A.
Juni, Rio P.
CLINICAL SCIENCE, 2022, 136 (15) : 1157 - 1178
[3] LncRNA H19 Overexpression in Endometriosis and its Utility as a Novel Biomarker for Predicting Recurrence
Liu, Songping
Xin, Weijuan
Tang, Xiaoyan
Qiu, Junjun
Zhang, Yajiao
Hua, Keqin
REPRODUCTIVE SCIENCES, 2020, 27 (09) : 1687 - 1697
[4] LncRNA H19: a novel player in the regulation of diabetic kidney disease
Wu, Qinrui
Huang, Fengjuan
FRONTIERS IN ENDOCRINOLOGY, 2023, 14
[5] Recent Advances of LncRNA H19 in Diabetes LncRNA H19 in Diabetes
Bi, Ye
Wang, Yao
Sun, Xianglan
HORMONE AND METABOLIC RESEARCH, 2022, 54 (04) : 212 - 219
[6] H19: A Regulatory Biomarker with Prognostic Value in Leukemias
Ghanavat, Majid
Khodadi, Elahe
Pezeshki, Seyed Mohammad Sadegh
Shahjahani, Mohammad
Shahrabi, Saeid
EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY, 2019, 3 (04): : 246 - 250
[7] The mechanism of lncRNA H19 in fibrosis and its potential as novel therapeutic target
Jiang, Xiaoying
Ning, Qilan
MECHANISMS OF AGEING AND DEVELOPMENT, 2020, 188
[8] Increased plasma levels of lncRNA H19 and LIPCAR are associated with increased risk of coronary artery disease in a Chinese population
Zhang, Zhen
Gao, Wei
Long, Qing-Qing
Zhang, Jian
Li, Ya-Fei
Liu, Dong-Chen
Yan, Jian-Jun
Yang, Zhi-Jian
Wang, Lian-Sheng
SCIENTIFIC REPORTS, 2017, 7
[9] The role of H19 lncRNA in conferring chemoresistance in cancer cells
Ghafouri-Fard, Soudeh
Shoorei, Hamed
Bahroudi, Zahra
Abak, Atefe
Taheri, Mohammad
BIOMEDICINE & PHARMACOTHERAPY, 2021, 138
[10] A genetic variant alters the secondary structure of the lncRNA H19 and is associated with dilated cardiomyopathy
Martens, Leonie
Ruehle, Frank
Witten, Anika
Meder, Benjamin
Katus, Hugo A.
Arbustini, Eloisa
Hasenfuss, Gerd
Sinner, Moritz F.
Kaeaeb, Stefan
Pankuweit, Sabine
Angermann, Christiane
Bornberg-Bauer, Erich
Stoll, Monika
RNA BIOLOGY, 2021, 18 : 409 - 415

← 1 2 3 4 5 →